Press Release

Feed Additives to Reach USD 62.90 Billion by 2033 as Two Prohibition-Created Categories Deliver Half the Growth

· Agriculture & Agritech

Pheonix Research, 21 November 2026. The global feed additives market will grow from USD 43,500.0 million in 2025 to USD 62,900.0 million in 2033, a compound annual growth rate of 4.72 per cent, according to a new report published today. The finding is not in the headline rate. It is in where the growth comes from.

Enzymes and gut-health additives hold 26.0 per cent of the 2025 market and will deliver 50.0 per cent of the growth over the forecast period. Gut health and zootechnical additives alone add USD 6,500.0 million at 8.65 per cent; enzymes add a further 16.5 per cent of growth at 7.07 per cent. Both categories exist at their present size because a regulator removed something else.

Phytase, the largest enzyme, is bought because it substitutes for inorganic feed phosphate. Gut-health products are bought because the European Union banned antibiotic growth promoters from 1 January 2006 and withdrew the medicinal use of zinc oxide. Regulation (EC) No 1831/2003, which removed antibiotics from the feed additive category, states in its own recital 26 that the transition must allow sufficient time for the development of alternative products to replace those antibiotics. The substitution market was legislated into existence.

That market is now being tested by the regulator that created it. Commission Implementing Regulation (EU) 2026/119 of 20 January 2026 refused authorisation of a carvacrol preparation as a zootechnical additive for weaned piglets — carvacrol being the principal active in oregano essential oil and the archetypal botanical replacement for zinc oxide. The refusal was on efficacy evidence, not safety: the European Food Safety Authority could accept two long-term efficacy trials showing significant effects, and Regulation (EC) No 429/2008 and the Authority’s guidance require three. Two further trials were set aside because of high diarrhoea incidence and mortality in the piglets.

“The category was created by regulation and is now constrained by regulation,” the report finds. “What is being licensed is the claim, not the molecule — and the claim is where the price comes from.”

The United States reached the same destination by the opposite lever. Under FDA Guidance for Industry #213, production and growth-promotion indications were withdrawn from all 31 affected applications, 115 feed products moved to veterinary feed directive status, 93 water products moved to prescription and 84 applications were withdrawn outright. The molecules stayed in the market. The indication that justified their price did not.

Feed tonnage is not the driver. Compound feed production grows from 1,390.0 million tonnes in 2025 to 1,529.0 million tonnes in 2033 at 1.20 per cent — a rate consistent with the industry’s own mill survey, which recorded global output of 1.39 billion tonnes in 2024, up 1.2 per cent. Revenue per tonne of compound feed rises from USD 31.29 to USD 41.14, or 3.48 per cent a year. That metric measures the value of the additive package bought per tonne, not inflation in the price of molecules, and the report treats it as a mix effect rather than a price index.

Three price-setting mechanisms operate in the market and the report warns against averaging them. Vitamins and trace elements are bought to a legal minimum, so their price is set by supply concentration — demonstrated on 7 August 2024 when BASF declared force majeure on selected vitamin A, vitamin E and carotenoid products after a fire at Ludwigshafen. Amino acids and enzymes are bought as an economic optimum, so their price is capped by the nutrient they replace. Products sold against a claim are capped by nothing measurable, which is where the growth and the margin sit, and where the authorisation risk now sits too.

Ownership is moving with the growth. On 11 February 2025 Novonesis agreed to acquire dsm-firmenich’s share of the Feed Enzyme Alliance and take over its sales and distribution activities for EUR 1.5 billion in cash, dissolving a partnership of more than 25 years and vertically integrating the enzyme value chain under a biologicals specialist, while dsm-firmenich repositioned away from animal nutrition.

The report discloses three deliberate exclusions from its perimeter: inorganic feed phosphates, mycotoxin binders and veterinary medicinal products are each sized separately, because counting a substitute and the product it displaces in one number would double-count a substitution. The value base is a construct with a disclosed band of USD 39,000–48,500 million. No regional split, market share table or transaction multiple is published, and the report states why in each case.

Global Feed Additives Market Report, Size, Share and Forecast 2026–2033 is available now. The full report covers the value chain, technology and innovation, competitive landscape, regulatory landscape, investment activity and market risk across six chapters.